XML 20 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 15,748,480 $ 20,637,045
Short-term investment securities 4,511,780 8,457,452
Interest receivable 94,375 112,247
Accounts receivable 277,831 294,199
Prepaid expenses and other current assets 375,830 280,555
Total current assets 21,008,296 29,781,498
Non-current assets:    
Investment in Alphazyme 284,709 284,709
Other assets 6,117 6,225
Total assets 21,299,122 30,072,432
Current liabilities:    
Accounts payable 1,547,953 1,013,099
Accrued expenses 709,560 489,756
Deferred research and development obligations 151,147 123,016
Deferred license revenue, current portion 147,059 0
Total current liabilities 2,555,719 1,625,871
Deferred license revenue, net of current portion 352,941 0
Total liabilities 2,908,660 1,625,871
Commitments and contingencies (Note 5)
Stockholders’ equity:    
Preferred stock, $.0001 par value: Authorized shares - 5,000,000; none issued and outstanding 0 0
Common stock, $.001 par value:Authorized shares - 100,000,000; issued shares - 40,332,659 and 39,747,659, outstanding shares - 28,079,157 and 27,494,157 as of June 30, 2021, and December 31, 2020, respectively 40,483 39,748
Additional paid-in capital 101,026,496 98,013,079
Treasury stock, shares held at cost - 12,253,502 (18,929,915) (18,929,915)
Accumulated deficit (63,746,602) (50,676,351)
Total stockholders’ equity 18,390,462 28,446,561
Total liabilities and stockholders’ equity $ 21,299,122 $ 30,072,432